A Performance Evaluation of the LumiraDx Point Of Care D-dimer Assay
EMBOL1
1 other identifier
interventional
1,000
2 countries
13
Brief Summary
In patients with symptoms of Venous Thromboembolism (VTE) (mainly deep vein thrombosis (DVT) or pulmonary embolism (PE)), the study will evaluate the agreement between the D-Dimer measurements from the LumiraDx POC D-Dimer assay and a reference method, as an aid in diagnosis, assessment and exclusion of DVT and PE.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2021
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 1, 2021
CompletedFirst Posted
Study publicly available on registry
February 4, 2021
CompletedStudy Start
First participant enrolled
March 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2022
CompletedSeptember 21, 2022
September 1, 2022
1.3 years
February 1, 2021
September 20, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Determine the accuracy of the LumiraDx POC D-Dimer assay when compared to a reference method in patients with suspected VTE.
Measurement of blood samples from patients with suspected VTE in a reference method and in the LumiraDx method to assess accuracy of the LumiraDx method.
2 months
Assessment of accuracy of using the D-Dimer cut-off set by the LumiraDx D-Dimer test in excluding patients with symptoms of VTE (DVT and PE) when used in combination with the pre-probability test (Wells Score).
Measurement of blood samples from patients with suspected VTE in the LumiraDx D-dimer assay in conjunction with pre-test probability score and final clinical outcome in order to set a clinical cut-off for the LumiraDx D-dimer assay
10 months
Study Arms (1)
Suspected VTE patients
EXPERIMENTALVenous blood draw of up to 20ML and up to 6 fingerstick capillary draws
Interventions
Eligibility Criteria
You may qualify if:
- Subject is greater or equal to 18 years of age Willing and able to provide written informed consent and comply with study procedures Symptoms of thromboembolic event
You may not qualify if:
- Suspected Sinus Venous Thromboembolism / Cerebral Venous Sinus Thromboembolism End-stage renal failure on haemodialysis Current anticoagulant therapy (Fragmin, LMWH) within the last 30 days Patient has previously participated in this study Life expectancy documented as \<30 days Haemodynamically unstable (e.g. cardiogenic shock) Patients taking anticoagulant therapy (DOACS, Warfarin, Heparins etc) within the last 30 days Patient deemed medically unfit to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
Universitäres Herz- und Gefäßzentrum Hamburg
Hamburg, 20246, Germany
Addenbrookes Hospital
Cambridge, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Epsom and St Helier Hospitals
Epsom, United Kingdom
Glsagow Royal Infirmary
Glasgow, United Kingdom
Queen Elizabeth University Hospital
Glasgow, United Kingdom
St Johns Hospital
Livingston, United Kingdom
Homerton University Hospital NHS Foundation Trust
London, United Kingdom
Royal London Hospital
London, United Kingdom
St Georges Hospital
London, United Kingdom
University College Hospital
London, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom
South Warwickshire Foundation Trust
Warwick, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Richard Body
Professor of Emergency Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 1, 2021
First Posted
February 4, 2021
Study Start
March 18, 2021
Primary Completion
June 30, 2022
Study Completion
September 1, 2022
Last Updated
September 21, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share